Sino Biopharmaceutical Limited
SBMFF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $51,730,000 | $69,064,057 | $75,138,205 | $79,281,527 |
| - Cash | $9,569,584 | $9,451,878 | $8,654,805 | $9,599,537 |
| + Debt | $9,783,841 | $12,580,244 | $13,981,963 | $12,117,513 |
| Enterprise Value | $51,944,257 | $72,192,423 | $80,465,363 | $81,799,503 |
| Revenue | $28,866,159 | $26,199,409 | $26,026,164 | $26,861,356 |
| % Growth | 10.2% | 0.7% | -3.1% | – |
| Gross Profit | $23,529,941 | $21,209,532 | $21,538,548 | $21,529,261 |
| % Margin | 81.5% | 81% | 82.8% | 80.1% |
| EBITDA | $6,108,662 | $6,979,427 | $6,691,347 | $19,873,846 |
| % Margin | 21.2% | 26.6% | 25.7% | 74% |
| Net Income | $3,499,834 | $2,331,939 | $2,543,570 | $14,608,412 |
| % Margin | 12.1% | 8.9% | 9.8% | 54.4% |
| EPS Diluted | 0.19 | 0.1 | 0.12 | 0.73 |
| % Growth | 90.6% | -16.9% | -83.6% | – |
| Operating Cash Flow | $6,615,120 | $6,065,734 | $6,265,155 | $5,366,294 |
| Capital Expenditures | -$960,102 | -$1,703,709 | -$1,705,612 | -$1,893,984 |
| Free Cash Flow | $5,655,018 | $4,362,025 | $4,559,543 | $3,472,310 |